All for Joomla All for Webmasters

D3 - Session 3 - Analytical Aspects of D-Dimer Assays

Rate this item
(12 votes)

Did you attend this webinar? Get your certificate

 

Questions/answers on the Session 3 - Analytical Aspects of D-Dimer Assays

A1. The validation of the threshold of an assay for the exclusion of Venous Thromboembolism (VTE) (for both, Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE)) requires testing of VTE suspected patients in whom the diagnosis has been established or excluded using a defined diagnostic algorithm that includes a pre-test probability, D-dimer testing and imaging techniques. For the population that has a final diagnosis of no VTE, it is also necessary to re-evaluate the patient after three months to confirm the negative diagnosis. These studies usually require thousands of patient samples tested in different institutions and countries. For details on these studies see CLSI H59-A (Quantitative D-dimer for the Exclusion of Venous Thromboembolic Disease; Approved Guideline)

A2. According to Professor Dempfle, the ideal D-dimer assay should have some characteristics such as a long linearity, not affected by Fibrinogen and its degradation products, accessible 24/7, providing results in less than 15 minutes, and evaluated in appropriate clinical studies. According to him these goals are most easily achieved by automated latex-enhanced Turbidimetric Immunoassays (Dempfle C-E. D-dimer testing and venous thromboembolism: four view points. J Thromb Haemost 2005; 3: 377–9). There are Turbidimetric assays in the market fulfilling these requirements.

A3. Usually the D-dimer assays, and in general all immunoassays, have some algorithms in the parameter settings of the instrument to identify this type of samples performing then automated dilutions of the sample. I am not aware of any standard protocol to perform. However, if an inhibitory prozone is suspected a 1:2 or 1:4 sample dilution should help to clarify it. In case of inhibitory prozone the diluted samples after multiplying by the dilution, will produce a result higher than the undiluted sample. Be aware of the linearity and test ranges established for the assay so that the obtained values are well within them.

A4. There is an association of D-dimer with High risk of VTE and with a poor prognosis in COVID patients. There is no standardization among D-dimer assays and the threshold level established for one method is not transferrable to another one. Therefore, results should be interpreted within each individual assay.

A5. There are some publications giving cutoffs values to stratify the risk (Thrombosis Research 196 (2020) 318–321), but again the cutoff should be established for each specific assay.

A6. D-dimer results may be different among D-dimer assays due to the specificity of the monoclonal antibodies used on each assay. As example of the difference between assays we could consider samples from patients with hyper fibrinolytic conditions or treated with profibrinolytic drugs. In these patients the fibrinolytic fragment will be of a small size. D-dimer assays with a preference for high molecular weight fibrin compounds will show lower levels of D-dimer antigen than assays, which detect the D-dimer epitope regardless of the molecular size of the fibrin compound. There could be also some interference increasing or decreasing the patient sample result producing discrepancies in the comparison of different assays. As example there could be interferences produced by Rheumatoid factor or Heterophilic antibodies.

Additional Info

  • Business Line: Hemostasis
  • Language: English
  • Speaker(s): Miquel Sales
  • Recorded Date: Tuesday, 06 April 2021
  • Duration: 23:31
Read 417 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection